Why the study?
Factors that limit the effectiveness of pharmacotherapy for hypertension with comorbid CAD in elderly obese patients, specifically laboratory and spectroscopy features of inflammation, needed identification.
Does obesity limit the effectiveness of lisinopril and bisoprolol therapy in elderly patients with hypertension and coronary artery disease?
Does obesity limit the effectiveness of lisinopril and bisoprolol therapy in elderly patients with hypertension and coronary artery disease?
Obesity limits the antihypertensive efficacy of lisinopril and bisoprolol in elderly patients with CAD, potentially due to obesity-associated inflammation, though non-obese patients showed greater renal function deterioration.
Answers are grounded in this paper and cite their sources.
Inflammation markers may limit HT response in elderly obese CAD patients; leaves open targeted strategies pending larger trials.
Object: to identify factors that limit the effectiveness of pharmacotherapy of hypertension (HT) with comorbid coronary artery disease (CAD) in elderly obese patients by determining laboratory and spectroscopy features related to inflammation. Material and methods: 60 patients (68.2 ± 5.9 y.o.) were observed and treated in Internal Medicine Department of University Clinic of Odessa National Medical University. Patients were divided into 2 groups. The 1st group included patients (n = 30) with body mass index (BMI) ≤25 kg/m2, HT and co-morbid CAD; the 2nd group (n = 30) - patients with BMI≥30 kg/m2, HT and with co-morbid CAD. For each patient’s group antihypertensive combination of Lisinopril and Bisoprolol was prescribed. The Laser correlation spectroscopy (LCS) was a special method for investigation. Results: before pharmacotherapy (PT) in both groups according to LCS 11-150 nm particles are prevailing. But in obese patients 75th percentile of 31-70 nm particles exceeds that one in non-obese group (56.7% vs 30.5%). During PT systolic blood pressure (SBP) value normalized in the patients of 1st group (without obesity), while in the obese patients (2nd group) SBP remained above target level. Creatinine level increased in patients of 1st group (without obesity) by 16.5 μmol / L (p <0.05) with a decrease in GFR by 17.1 ml/min/1.73 m2 (P <0.05). LCS data during PT show increase of 11-30 nm and decrease of 75-150 nm particles in non-obese patients, while in obese patients 71-150 nm particles are prevailing and 150 nm particles have appeared (p<0.05). Conclusions: 1. In elderly hypertensive patients with concomitant CAD, obesity is a factor limiting the effectiveness of complex antihypertensive therapy. 2. An increase of proportion of allergic-directed and appearance of autoimmune-directed homeostatic shifts in serum according to LCS are associated with a decrease of antihypertensive therapy efficacy in elderly hypertensive patients with CAD and obesity. 3. In hypertensive non-obese patients with CAD under the influence of complex antihypertensive therapy deteriorating of renal function is observed while in obesity renal function is not changed. 4. Homeostatic changes revealed in the second group by LCS values probably reflect manifestation of low grade inflammatory process caused by excessive activity of adipose tissue.
No takes yet. Share an insight, caveat, or question.
Tofan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: